Loading
FORT MYERS — Cancer testing firm Neogenomics says it has developed software that will help it automate the reading and interpretation of cancer tests.
The Fort Myers-based company says it has applied for a patent for the software and will consider licensing it to other cancer-testing providers.
Currently, employees conduct certain cancer tests manually, and most laboratories only count 50 cells. The new software will automate that process and is more accurate because it can count more cells. This is important for lung-cancer patients, for instance, who require tailored therapy for successful treatment, the company says.
“We believe these types of algorithms will be instrumental in helping to answer complex clinical questions and reducing the dependence on subjective interpretations,” says Maher Albitar, Neogenomics' chief medical officer and director of research and development.
Neogenomics is a publicly traded company (symbol: NGNM; recent price: $2.65).
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
